Evidence map›Paper›PMID 34059099›Full record

ArticleChinese medicine2021

Anti-angiogenesis and anti-metastasis effects of Polyphyllin VII on Hepatocellular carcinoma cells in vitro and in vivo.

Chao Zhang, Qingrui Li, Guozheng Qin, Yi Zhang, Chaoying Li, Liwen Han, Rongchun Wang, Shudan Wang, Haixia Chen, Kechun Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. [Polyphyllin VII inhibits osteosarcoma xenograft growth in mice by inducing ferroptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  3. Article
  4. Article
  5. Frontiers in pharmacology · 2025
    Review
  6. Saponins ofMolecules (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Chao ZhangBeijing University of Chinese Medicine, Beijing, 100102, China.
Qingrui LiBeijing University of Chinese Medicine, Beijing, 100102, China.
Guozheng QinYunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, 650021, China.
Yi ZhangBeijing University of Chinese Medicine, Beijing, 100102, China.
Chaoying LiSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, China.
Liwen HanInstitute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250062, China.
Rongchun WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.
Shudan WangSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, China.
Haixia ChenTianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, China.
Kechun LiuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China. hliukch@sdas.org.
Chengwei HeState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999078, China. chengweihe@umac.mo.ORCID http://orcid.org/0000-0003-4701-2984
Beijing University of Chinese Medicine · CNChangchun University of Chinese Medicine · CNQilu University of Technology · CNShandong First Medical University · CNTianjin University · CNUniversity of Macau · MOYunnan University · CN

Funding

China Postdoctoral Science Foundation 2019M650599Fundamental Research Funds for the Central Universities 2020-JYB-XJSJJ-011National Key R&D Program of China 2018YFC1707300National Natural Science Foundation of China 82003972Science and Technology Development Fund, Macau SAR 0024/2020/A1Science and Technology Development Fund, Macau SAR 070/2017/A2University of Macau MYRG2018-00176-ICMS
6 · The paper itself

Abstract

backgroundPolyphyllin VII (PP7), a steroidal saponin from P. polyphylla has been found to exert strong anticancer activity. Little is known about the anti-angiogenesis and anti-metastasis properties of PP7. In this study, the anti-angiogenic and anti-metastatic effects of PP7 on HCC and the molecular mechanisms were evaluated.

methodsEffect of PP7 on angiogenesis was assessed by tube formation assay and applied a transgenic Tg(fli1:EGFP) zebrafish model. Effects of PP7 on tumor metastasis and invasion were examined in cell migration and invasion assay, zebrafish tumor xenograft models and lung metastasis mouse models. The protein levels were examined by Western blotting.

resultsPP7 significantly decreased the tube formation of human umbilical vein endothelial cells, the number and length of ISVs and SIVs of transgenic zebrafish, and the metastasis and invasion of cancer cells in vitro and in vivo. The anti-angiogenic and anti-metastatic effects of PP7 in HepG2 cells were attributable, at least partially, to downregulated NF-κB/MMP-9/VEGF signaling pathway.

conclusionThis study demonstrates that PP7 possesses strong anti-angiogenesis and anti-metastasis activities, suggesting that PP7 could be a potential candidate agent for HCC treatment.

Indexed as

Anti-angiogenesisAnti-metastasisHepatocellular carcinoma cellsNF-κB/MMP-9/VEGF pathwayPolyphyllin VII

Identifiers

PMID34059099
PMCPMC8166003
OpenAlexW3164021547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.